obesity research comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-12-17. Where a claim depends on a specific study, the study is described rather than over-claimed.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide fragment | Not a full hormone |
| Molecular target | Proposed adipose tissue lipolysis | Receptor details uncertain |
| Typical research dose | Not established for clinical use | Doses vary across studies |
| Stability in solution | Limited; store cold | Avoid repeated freeze-thaw |
| Regulatory status | Not approved as a drug | Varies by country |
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
"Adequate calcium and regular exercise may help achieve strong bones in children and adolescents and reduce the risk of osteoporosis in older adults. An adequate intake of vitamin D is also necessary." Japan: Foods with Nutrient Function Claims (FNFC)
=== Personality Tests === Jung has influenced management theory because managers and executives create an appropriate "management persona" (a corporate mask) and a persuasive identity, and they have to evaluate what sort of people the workers are, to manage them (for example, using personality tests and peer reviews). The Myers–Briggs Type Indicator (MBTI), a psychometric instrument mostly popular with non-psychologists, as well as the concepts of socionics, were developed from Jung's model of psychological types. The MBTI is considered pseudoscience and is not widely accepted by researchers in the field of psychology.
The four substrates of this enzyme are (−)-menthol, reduced nicotinamide adenine dinucleotide phosphate (NADPH), oxygen, and a proton. Its products are p-menthane-3,8-diol, oxidised NADP+, and water. This enzyme is an oxidoreductase, acting on paired donors, with molecular oxygen as oxidant and incorporating one of its atoms. The systematic name of this enzyme class is (−)-menthol,NADPH:oxygen oxidoreductase (8-hydroxylating). This enzyme is also called l-menthol monooxygenase.
== Church service == Prior to his call to full-time service, Kearon's service in the church included being president of the Bristol England Stake and area seventy. At the time of his call as a general authority, Kearon was living in Clevedon, which is a town in North Somerset, England. In 2011, he was appointed as an assistant executive director of the church's priesthood and media services departments. From August 2012 to August 2015, he served as a counselor in the presidency of the church's Europe Area, before becoming the area's president in August 2015. In May 2017, it was announced that Kearon would become a member of the Presidency of the Seventy on August 1, with responsibility for the church's North America Northwest and North America West areas. Kearon has been vocal on the topic of religious freedom, stating that "religious freedom means nothing if you protect your own religious practice while neglecting the practice of others, especially those who might be less secure and able to defend themselves. It only works if you protect the rights of everyone." In 2016, he addressed European Commission officials at a European Union summit asking for assistance during the refugee crisis. Kearon was quoted in a New York Times op-ed with regards to his work with refugees saying, “Their story is our story, not that many years ago.” While serving as president of the church's Europe Area, Kearon initiated programs to assist refugees in the area and also led out in the church working to support existing programs to help refugees..
On January 26, 2006, Chipotle made its initial public offering (IPO) after increasing the share price twice due to high pre-IPO demand. At the time, Chipotle had 500 stores. In its first day as a public company, the stock rose exactly 100%, resulting in the best U.S.-based IPO in six years, and the second-best IPO for a restaurant after Boston Market. The money from the offering was then used to fund new store growth. In March 2005, Monty Moran was appointed president and chief operating officer of Chipotle while Ells remained chairman and CEO. In October 2006, McDonald's fully divested from Chipotle. This was part of a larger initiative for McDonald's to divest all of its non-core business restaurants—Chipotle, Donatos Pizza, and Boston Market—so that it could focus on the main McDonald's chain. McDonald's had invested approximately $360 million into Chipotle, and took out $1.5 billion. McDonald's had attempted to get Chipotle to add drive-through windows and a breakfast menu, which Ells resisted. In 2008, Chipotle opened its first location outside of the United States in Toronto. In January 2009, president and chief operating officer Monty Moran was promoted to co-CEO, a position that he would share with Ells, while Moran retained his president position. In a list of fastest-growing restaurant chains in 2009, Chipotle was ranked eighth, based on increases in U.S. sales over the past year, and in 2010 Chipotle was ranked third. Consumer Reports ranked Chipotle as the best Mexican fast-food chain in 2011. The company serves approximately 750,000 customers per day.
Sources: en.wikipedia.org
In addition to other 2Cs, derivatives of 2C-B such as 2C-B-FLY and 25B-NBOMe have been developed and emerged as well-known novel designer drugs. 2C-B-FLY was Ann Shulgin's favorite psychedelic, which she especially enjoyed in terms of enhanced eroticism, and preferred "a bit more" than 2C-B.
Vice writer Patrick Klepek felt that the Headcrab was an iconic enemy known by people outside the Half-Life fandom, stating that due to it becoming more familiar, it became less intimidating, citing the fact that it was made into a plush. He felt that the Headcrabs in Half-Life: Alyx were responsible for making Headcrabs scary again, stating that it being a virtual reality game made its attacks that much more frightening. He felt that the Headcrabs being scary served as proof of how well Alyx works as a video game. Dread Central writer Justin Wood felt similarly about the virtual reality technology, stating that the sight of Headcrabs jumping at the player created "visceral reactions", as well as making him uncomfortable to hear them creeping around. Kotaku writer Nathan Grayson stated that, through his time playing Alyx, he had never gotten used to the "nauseating sense of dread" from the fear of being attacked by Headcrabs. He felt that this went beyond just being in virtual reality, praising the development team for managing to create such good sound design and animation that being accosted by Headcrabs inspired genuine fear in him. Twitch producer Mary Kish regarded Alyx as one of her favorite video games of 2020, stating that it being "genuinely scary" was a large part of why she liked it. She discussed how the Headcrabs function in it, which caused her to hold her breath in response to a Headcrab's presence, believing they pulled off a sense of danger well.
=== Intracrines in organogenesis === The development of organs relies on complex signaling interactions that regulate cell proliferation, migration, and differentiation. Intracrines such as dynorphin B and transforming growth factor-beta (TGF-β) have been implicated in cardiac development, promoting the differentiation of cardiac progenitor cells and guiding their maturation into functional cardiomyocytes. In cardiac embryogenesis, intracrine feedback loops involving dynorphin B and Nkx-2.5 (a homeodomain transcription factor) have been shown to drive the expression of cardiac-specific genes, reinforcing the role of intracrines in orchestrating organ development. Furthermore, intracrines contribute to the spatial and temporal regulation of developmental cues. Homeodomain proteins, which are critical for embryonic patterning, can be secreted and internalized by neighboring cells, enabling coordinated differentiation across tissues. This form of intracrine signaling ensures that developing structures, such as the eye or heart, maintain proper cellular identity and function.
== History == The NAFBL was formed in January 1895 and in March 1895, the NAFBL began operation as the third significant U.S. soccer league. It drew its teams primarily from northern New Jersey and New York City. Few records exist for the league, but the teams and standings for four of the five seasons do exist. After its first spring-summer season in 1895, the NAFBL moved to a winter schedule in the fall of 1895. On December 16, 1895, the NAFBL opened its second season with a game pitting the Kearny Scottish-Americans and the International Athletic Club. In 1899, a deep recession, accompanied by the Spanish–American War led to the collapse of several athletic leagues and teams, among them the NAFBL. On August 14, 1906, the league was revived and continued in operation until 1921. That year, several of the top NAFBL teams, frustrated by the amateur/semi-professional nature of the league, joined with other top North Atlantic U.S. teams to form the first fully professional U.S. soccer league, the American Soccer League.
Sources: en.wikipedia.org
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.
Because it is a fragment rather than full growth hormone, it is generally described as lacking growth-promoting effects. Some studies suggest it may influence fat metabolism without the same systemic growth effects, though evidence is limited.
Human trials have measured body weight, fat mass, lean mass, lipid levels, and adverse events. Most have been small or short-term, so conclusions about long-term outcomes are limited.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.